Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials
详细信息 查看全文
- 作者：S.K. Kang&lowast ; ; &dagger ; ; stella.kang@nyumc.org" class="auth_mail" title="E-mail the corresponding author ; A. Volodarskiy&Dagger ; ; E.L. Ohmann§ ; ; A.V. Balar¶ ; ; S. Bangalore¶ ;
- 关键词：Meta-analysis ; renal cell carcinoma ; targeted therapy ; tyrosine kinase inhibitor
- 刊名：Clinical Oncology
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：28
- 期：5
- 页码：334-341
- 全文大小：969 K
文摘
- •
VEGFR inhibitors are associated with improved progression-free survival and objective response rate compared with the multikinase inhibitor sorafenib.
- •
Selective VEGFR inhibitors show similar overall survival and discontinuation due to adverse events compared with sorafenib.
- •
Toxicity profiles for the selective versus multikinase inhibitors are overall similar for the most common adverse effects.